Mechanisms of cell dysfunction by aggregation dynamics of polyQ containing prote...
Mechanisms of cell dysfunction by aggregation dynamics of polyQ containing proteins
Protein aggregation is a hallmark of several ageing-related neurodegenerative diseases, such as Huntington’s disease (HD), Alzheimer’s disease and prion-mediated diseases. Different cellular pathways influence the rate of aggregat...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SAF2015-65371-R
ALTERACIONES EN EL PROCESAMIENTO DEL ARN EN LA ENFERMEDAD DE...
460K€
Cerrado
SAF2012-34177
CONVERGENCIA DE ALTERACIONES GENICAS, TRANSCRIPCIONALES Y TR...
386K€
Cerrado
RTI2018-096322-B-I00
PROTEINAS DE UNION AL ARN EN LA ETIOLOGIA DE LA ENFERMEDAD D...
411K€
Cerrado
SAF2009-08233
PAPEL DEL ESTRES DE RETICULO ENDOPLASMICO Y DE LA QUINASA GS...
359K€
Cerrado
SAF2009-08374
ALTERACION DE LA AUTOFAGIA EN LA ENFERMEDAD DE HUNTINGTON
113K€
Cerrado
PID2019-109276RA-I00
BASES ESTRUCTURALES DE LA TOXICIDAD DE ENSAMBLADOS TEMPRANOS...
157K€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Protein aggregation is a hallmark of several ageing-related neurodegenerative diseases, such as Huntington’s disease (HD), Alzheimer’s disease and prion-mediated diseases. Different cellular pathways influence the rate of aggregation, and clearance of intermediate protein species and aggregates in the cell (for example, autophagy or proteasomal degradation). Many signalling pathways regulate these processes. These signalling events, and the molecular pathways downstream are not completely understood. In HD there is an inverse correlation between the number of CAG triplets found in mutated huntingtin (htt) and the age-of-onset of the symptoms. However, there is a wide variation in the age-at-onset of the disease among carriers of short mutant glutamine tracts, suggesting that the genetic background strongly influences the severity of the disease. Hence the broad objective of this proposal is to find molecules that modulate protein aggregation.
We will use in vivo (C. elegans) and in vitro (mammalian cells) models of HD to find new molecules and pathways that modulate aggregation and toxicity induced by polyglutamines. The second objective of this proposal is to understand the mechanism by which mHtt toxic species alter cellular processes, with special focus on pre-synaptic function.